Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 30, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Bosutinib Tablets, 100 mg and 500 mg".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received final approval from the USFDA to manufacture and market Bosutinib Tablets in 100 mg and 500 mg strengths in the United States. Bosutinib is a generic version of Bosulif, originally developed by Pfizer, and is used in the treatment of chronic myeloid leukemia (CML). This is an ANDA (Abbreviated New Drug Application) approval, meaning Alembic can now commercially launch the product in the US market. The company had previously secured tentative approval for this product. US generics remain a key growth driver for Alembic's export business, contributing meaningfully to overall revenue.
Positive for shareholders — final approval allows commercial launch in the US market, opening a new revenue stream in the oncology generics space. The stock may see mild positive sentiment, though actual financial impact depends on market share capture and pricing dynamics.